Want to see HK:3933 full AI Analyst Report?
3933 Stock Chart & Stats
HK$8.77
-HK$0.10(-1.10%)
At close: 4:00 PM EDT
HK$8.77
-HK$0.10(-1.10%)
Day’s Range― - ―
52-Week RangeHK$7.61 - HK$16.02
Previous CloseN/A
Volume4.20M
Average Volume (3M)7.74M
Market Cap
HK$15.60B
Enterprise ValueHK$10.04K
Total Cash (Recent Filing)HK$11.73B
Total Debt (Recent Filing)HK$5.95B
Price to Earnings (P/E)24.3
Beta0.87
Next Earnings
Mar 30, 2027EPS Estimate
0.25Next Dividend Ex-DateN/A
Dividend Yield3.78%
Share Statistics
EPS (TTM)0.28
Shares Outstanding1,970,276,500
10 Day Avg. Volume6,061,992
30 Day Avg. Volume7,737,463
Financial Highlights & Ratios
PEG Ratio-0.39
Price to Book (P/B)1.13
Price to Sales (P/S)1.49
P/FCF Ratio22.94
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$12.65Price Target Upside44.27% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)0.51
Revenue Forecast (FY)HK$12.36B
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetModerate leverage and steadily expanding equity provide financial resilience and preserve flexibility for investment, working capital, and product development. Asset growth also supports operating scale, giving the company a stronger base from which to manage pharmaceutical-market cycles.
Solid Pharmaceutical ProfitabilityHealthy gross and net margins indicate that the company retains meaningful profit generation across its pharmaceutical operations despite recent pressure. This profitability can support reinvestment in products and capacity while providing a durable buffer against competitive pricing and cost pressures.
Positive Operating Cash FlowPositive operating cash flow shows that the core business is converting sales into internally generated funds, rather than relying entirely on external financing. Continued cash generation can help fund operations, investment, and shareholder returns while reinforcing balance-sheet resilience.
Bears Say
Revenue ContractionThe shift from strong earlier expansion to stagnation and then contraction signals weaker near-term demand or market penetration across the portfolio. If sustained, slower revenue growth could limit operating leverage, reduce investment capacity, and make future earnings recovery more difficult.
Margin And ROE CompressionFalling margins and returns on equity show that the company is generating less profit from both revenue and its capital base. Persistent compression would weaken earnings quality, reduce the benefit of scale, and constrain the returns available from future growth or reinvestment.
Weak Cash ConversionLow and volatile free-cash-flow conversion means reported profits are not consistently translating into deployable cash. That reduces the company’s ability to fund expansion, dividends, or debt reduction internally and makes earnings less dependable as a measure of financial strength.
The United Laboratories International Holdings News
3933 FAQ
What was The United Laboratories International Holdings Limited’s price range in the past 12 months?
The United Laboratories International Holdings Limited lowest stock price was HK$7.61 and its highest was HK$16.02 in the past 12 months.
What is The United Laboratories International Holdings Limited’s market cap?
The United Laboratories International Holdings Limited’s market cap is HK$15.60B.
When is The United Laboratories International Holdings Limited’s upcoming earnings report date?
The United Laboratories International Holdings Limited’s upcoming earnings report date is Mar 30, 2027 which is in 190 days.
How were The United Laboratories International Holdings Limited’s earnings last quarter?
The United Laboratories International Holdings Limited released its earnings results on Aug 31, 2026. The company reported HK$0.206 earnings per share for the quarter, beating the consensus estimate of HK$0.152 by HK$0.054.
Is The United Laboratories International Holdings Limited overvalued?
According to Wall Street analysts The United Laboratories International Holdings Limited’s price is currently Undervalued.
Does The United Laboratories International Holdings Limited pay dividends?
The United Laboratories International Holdings Limited pays a Annually dividend of HK$0.299 which represents an annual dividend yield of 3.78%. See more information on The United Laboratories International Holdings Limited dividends here
What is The United Laboratories International Holdings Limited’s EPS estimate?
The United Laboratories International Holdings Limited’s EPS estimate is 0.25.
How many shares outstanding does The United Laboratories International Holdings Limited have?
The United Laboratories International Holdings Limited has 1,970,276,500 shares outstanding.
What happened to The United Laboratories International Holdings Limited’s price movement after its last earnings report?
The United Laboratories International Holdings Limited reported an EPS of HK$0.206 in its last earnings report, beating expectations of HK$0.152. Following the earnings report the stock price went down -3.398%.
Which hedge fund is a major shareholder of The United Laboratories International Holdings Limited?
Currently, no hedge funds are holding shares in HK:3933
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
The United Laboratories International Holdings Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-50.10%
12-Months-Change
Fundamentals
Return on Equity
3.78%
Trailing 12-Months
Asset Growth
15.21%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
The United Laboratories International Holdings Limited
The United Laboratories International Holdings Limited functions as an investment holding company with a primary focus on the pharmaceutical sector. Its multifaceted operations cover the entire lifecycle of drug development and commercialization, from pioneering research and development to manufacturing, distribution, and sales. The company structures its diverse business into three core divisions: Bulk Medicine, Intermediate Products, and Finished Goods. Its broad product portfolio features a variety of medications, such as oral antibiotics, injectable antimicrobials, cold and cough remedies, ophthalmic solutions, antiviral and anti-hepatitis B drugs, diabetes treatments, topical dermatological preparations, cardiovascular and neurological pharmaceuticals, vitamins, and empty gelatin capsules, alongside active pharmaceutical ingredients (APIs) and other intermediary compounds. Furthermore, the company manufactures and markets soft capsule shells, holds trademarks, engages in pharmaceutical trading, and provides management services. Founded in 1990 and headquartered in Yuen Long, Hong Kong, the firm maintains a significant global reach, conducting business throughout the People's Republic of China, Europe, India, the Middle East, South America, other Asian territories, and internationally.
3933 Stock 12 Month Forecast
Average Price Target
HK$12.65
▲(44.27% Upside)
Technical Analysis
China Medical System Holdings
―
Livzon Pharmaceutical Group
―
China Resources Pharmaceutical Group Ltd.
―
Consun Pharmaceutical Group Ltd.
―
Grand Pharmaceutical Group Limited
―